An unfortunate reflection of appalling stewardship by a board living off 'the good old times' of years gone by (and themselves remunerated an exorbitant amount for such a small company).
All to often seen these days. Boards full of promoted mates scratching each other's backs and quite simply not driving or challenging their enterprise or its management.
- Forums
- ASX - By Stock
- KOV
- Executive Remuneration
Executive Remuneration, page-2
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KOV (ASX) to my watchlist
|
|||||
Last
$10.69 |
Change
0.270(2.59%) |
Mkt cap ! $125.5M |
Open | High | Low | Value | Volume |
$10.50 | $10.69 | $10.50 | $241.8K | 22.77K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2600 | $10.65 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$10.69 | 3915 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2600 | 10.650 |
1 | 4725 | 10.550 |
1 | 30 | 10.530 |
1 | 1328 | 10.520 |
1 | 800 | 10.430 |
Price($) | Vol. | No. |
---|---|---|
10.690 | 3915 | 2 |
10.720 | 2500 | 1 |
10.740 | 95 | 1 |
11.000 | 620 | 2 |
11.620 | 650 | 1 |
Last trade - 15.58pm 09/08/2024 (20 minute delay) ? |
Featured News
NEWS
Is oil undervalued?
BOE
Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
KOV (ASX) Chart |